Relmada Therapeutics
RLMD
72 hedge funds and large institutions have $393M invested in Relmada Therapeutics in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 14 closing their positions.
72,200% more call options, than puts
Call options by funds: $7.95M | Put options by funds: $11K
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
3.93% less ownership
Funds ownership: 69.12% → 65.19% (-3.9%)
4% less funds holding
Funds holding: 75 → 72 (-3)
16% less capital invested
Capital invested by funds: $469M → $393M (-$76.4M)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$2.9M |
| 2 |
Aviva
London,
United Kingdom
|
+$2.35M |
| 3 |
SG Americas Securities
New York
|
+$2.1M |
| 4 |
Bank of New York Mellon
New York
|
+$1.74M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.95M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.73M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$2.23M |
| 4 |
Millennium Management
New York
|
-$1.67M |
| 5 |
Morgan Stanley
New York
|
-$1.25M |
RLMD Hedge Fund Activity: Q3 2020 in Review
72 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2020, worth a combined $393M — down 16% from $469M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RLMD and 11 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 22 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $2.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.95M sold.
- 72 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2020, down from 75 in Q2 2020.
- Funds reported $393M of Relmada Therapeutics stock for Q3 2020, down 16% quarter-over-quarter.
- 11 funds opened new Relmada Therapeutics positions in Q3 2020 and 14 closed out, a net change of -3 holders.
- The largest Relmada Therapeutics buyer in Q3 2020 was Avoro Capital Advisors, an estimated $2.9M added.
- The largest Relmada Therapeutics seller in Q3 2020 was EcoR1 Capital, an estimated $8.95M sold.
Based on aggregated 13F filings for Q3 2020.